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1. Introduction
The term autophagy (from the Greek, auto – oneself, phagy - to eat or autophagy-self eating)
was first coined for structures that were observed under an electron microscope and that were
consisted of single-or double-membrane lysosomal-derived vesicles containing cytoplasmic
particles including organelles during various stages of disintegration [1,2]. Autophagic cell
death or autophagy is a type of cell death that occurs in the absence of chromatin condensation
but is associated with the massive autophagic vacuolization of the cytoplasm [3]. Autophagy
is the process by which cells recycle their own nonessential, redundant, and damaged
organelles and macromolecular components. Autophagy also plays its role in the suppression
of tumor growth, deletion of toxic misfolded proteins, elimination of intracellular microor‐
ganisms, and pathogenesis of several diseases such as cancer and muscular disorders [4-6].
Like apoptosis, autophagy is an evolutionary conserved process that occurs in all eukaryotic cells
[7]. Autophagy can be triggered as a result of nutrient deprivation, differentiation, and develop‐
mental factors. In contrast to the apoptosis, cells that die with an autophagic morphology have
little or no association with phagocytes. Excessive autophagy may be attributed to crumple the
cellular functions and induce cell death directly. On the other hand, autophagy can lead to the
execution of apoptotic or necrotic cell death programs. It has also been suggested that autopha‐
gy may occur as a process alongside apoptosis or it may play a supportive role in apoptosis [8].
Autophagy and apoptosis differ in morphological characteristics. The causative relationship
between these two has not been elucidated yet. The increase in autophagosomes indicates an
increase  in  autophagic  activity  or  decreased  autophagosome-lysosome fusion.  The  most
important characteristic of autophagic cell death is the appearance of double- or multiple-
membrane vesicles (autophagosomes) in cytoplasm, which sequesters cytoplasmic compo‐
nents and organelles such as mitochondria and endoplasmic reticulum [9].
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1.1. Role of autophagy in cancer
Cancer is an umbrella term covering a plethora of conditions characterized by unscheduled
and uncontrolled cellular proliferation [10]. Cancer is the second leading cause of mortality
with an incident rate of about 2.6 million cases reported annually across Europe and USA [11].
Autophagy has a multifaceted role in cancer [12,13]. Even though, present studies are only
associative, autophagy most probably functions to curtail neoplasia [14]. There are several
oncogenes including PI3K and Akt family members, MTOR, and Bcl2 restrain autophagy,
while tumor suppressors such as PTEN, HIF1A, and TSC2 endorse autophagy [15]. Paradox‐
ically, autophagy is double-edged sword having a role in promoting both cell survival and cell
death [16]. The role of autophagy in the demise of a cell is contentious [17]. Despite the fact
that number of autophagosomes increases in some dying cells, it is still ambiguous whether
these structures are involved or just facilitate cell death [18]. The genetic deletion of key
autophagic genes pick up the pace rather than to inhibit cell death, which accentuate the
predominant survival role of autophagy [19].
Although, apoptosis and autophagy are markedly different processes but several lines of
evidence have portrayed interplay between these two processes; such as the proteins from the
Bcl2 regulate both autophagic and apoptotic machinery [17]. Furthermore, three types of
interplay exist between autophagic and apoptotic pathways. Both apoptosis and autophagy
function as a collaborator to induce cell death; autophagy act as anagonistic to hamper
apoptotic cell death by promoting cell survival, autophagy act as enabler of apoptosis, and
contributing in certain morphological and cellular events that occur during apoptotic cell death
without leading to death in itself [8].
1.1.1. Autophagy in tumor suppression
Cancer is considered as a complex group of genetic disorder with multiple causes. It is thought
to be involved in perturbation of several different pathways that control and regulate the cell
differentiation, cell proliferation, and cell survival. Another enigma has been the role of autoph‐
agy in tumor suppression; cancer may be protected by macroautophagy by sequestering
damaged organelles, permitting cellular differentiation, increasing protein catabolism, and
promoting autophagic cell death [20]. There are some experimental evidences which support the
possibility that autophagy promotes the survival of nutrient-starved tumor cells and in turn
contribute to cancer. Recent advances give deep insight into the molecular mechanism of
autophagy. These findings more likely favor the concept that autophagy and defects in autoph‐
agy contribute to tumor suppression and oncogenesis respectively. Biochemical studies and
genetic evidences designed in mammalian cells and in C. elegans respectively suggest that
autophagy is positively regulated by the PTEN tumor suppressor gene and negatively regulat‐
ed by the oncogenic Class I phosphatidylinositol 3-kinase signaling pathway. Furthermore Beclin
1, the mammalian APG gene has tumor suppressor activity and maps a tumor susceptibility locus,
which is commonly deleted in human breast and ovarian cancers. The molecular mechanism of
oncogenesis in human cancer can be fairly understood through genetic disruption of autopha‐
gy control. Such insights may foster the development of novel approaches to restore autopha‐
gy in the chemoprevention or treatment of human malignancies [21].
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Autophagy is a kind of homeostatic mechanisms which accelerates and induces tumorigenesis
when it disrupts. It removes the damaged organelles/proteins, limiting cell growth and causes
genomic instability which are involved in the tumor suppression mechanism [22]. The
experimental studies show that Beclin 1 is a haploin sufficient tumor suppressor gene. As this
protein is used for autophagy induction and Beclin 1+/− mice were shown to be tumor prone
[23]. The excessive stimulation of autophagy due to Beclin 1 protein overexpression can inhibit
tumor development [24]. The accumulation of p62/SQSTM 1 protein aggregates, damaged
mitochondria, and misfolded proteins due to the formation of molecular link between
defective autophagy and tumorigenesis generate the reactive oxygen species (ROS) and
genomic instability is observed due to the damage of DNA. ROS and the DNA damage can be
prevented by knockdown of p62/SQSTM 1 in autophagy-defective cells [22]. The relationship
between defective autophagy and p62/SQSTM 1 accumulation with tumorigenesis is further
evidenced from a study involving p62/SQSTM 1−/− mice protected from Ras-induced lung
carcinoma compared with wild-type animals [25]. It is further concluded that autophagy may
also provide protection against tumorigenesis by limiting necrosis and chronic inflammation,
which are associated with the release of pro-inflammatory HMGB1 [26]. All above findings
give a concentric remark about the role of the autophagy as a mechanism of tumor suppression.
1.1.2. Autophagy in tumor cell survival
The autophagy plays a predominant role in cancer cells to confer stress tolerance, which serves
to maintain tumor cell survival [20]. The induction of cell death mainly relates to the knock‐
down of essential autophagy genes in tumor cells [27]. Cancer cells have high metabolic
demands. The exposure of increased cellular proliferation and in vivo models to metabolic
stress was shown to impair the survival of autophagy-deficient cells with compared to
autophagy-proficient cells [22]. Moreover, cytotoxic and metabolic stresses, including hypoxia
and nutrient deprivation, can activate autophagy for recycling of ATP and in maintaining the
cellular biosynthesis and survival. Autophagy is mainly considered to be induced in hypoxic
tumor cells from regions that are distal to blood vessels and HIF-1α-dependent and -inde‐
pendent activation have been described [28]. The expression of angiogenic factors, such as
vascular endothelial growth factor, platelet-derived growth factor, and nitric oxide synthtase
are HIF-1α [28]. Human pancreatic cancer cell lines have increased basal levels of autophagy.
These enable tumor cell growth by maintaining cellular energy production. Autophagic
inhibition may lead to tumor regression and extended survival in pancreatic cancer xenografts
[29]. In the survived cancer cells autophagy generates a state of dormancy in residual cancer
cells that may further contribute to tumor recurrence and progression [30]. The increased
efficacy of anticancer drugs, in response to inhibition of autophagy, supports cytoprotective
role of autophagy in cancer cells. The research data indicate that H-ras or K-ras bearing
activating mutations show high basal levels of autophagy in human cell lines irrespective of
abundant nutrients [31]. The cell growth in these cell lines was associated with autophagic
proteins. In conclusion, it is the autophagy that maintains tumor cell survival. Moreover it
suggests that by blocking autophagy in tumors is an effective treatment approach [21].
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1.2. Cross-talk between different cell-death modes
Under the physiological conditions cells show compliance with respect to how they die
responding various stimuli. There are certain factors such as the type of cell, type and intensity
of noxious signals, and ATP concentration that determine how cells die [19]. Acute myocardial
ischemia (which is involved in the sudden fall in ATP level) induces necrosis, whereas chronic
congestive heart failure (with more modest yet chronic decrease in ATP) induces apoptosis
[32]. Although, a particular cell death program may preferentially be triggered in different
circumstances and multiple pathways may be activated concomitantly or successively in
individual dying cells [33]. Furthermore, there seems to exist an interplay among different cell
death pathways. Even though apoptosis and autophagy both bear distinct morphological
characteristics and physiological processes, still there exist some intricate interrelationships
between them. Apoptosis and autophagy, under some conditions, play synergistic effects;
while other times autophagy onsets only when apoptotic suppression occurs. Moreover, recent
studies have markedly pointed out the existence of strong interconnection between apoptosis
and autophagy and also strengthened the concept of simultaneous regulation of both A’s that
trigger cell death in cancer. The obstruction of a particular pathway of cell death may not avert
the annihilation of the cell but instead may recruit an alternative path such as the broad-
spectrum anti-apoptotic caspase inhibitors, zVAD-fmk, modulates the three major types of cell
death. Addition of zVAD-fmk blocks apoptotic cell death, sensitizes cells to necrotic cell death,
and induces autophagic cell death [34].
The overexpression of anti-apoptotic proteins may lead to the survival of injured cells where
critical metabolites are provided by autophagy [35]. Nevertheless, if death stimuli persist, anti-
apoptotic pathways and autophagy are unlikely to prolong and necrosis ensues [36]. Most
likely, NF-κB, ATG5, ATP, and PARP function as molecular switches that determine whether
a cell undergoes apoptosis, necrosis, or autophagy [37-39]. Protein p53 also modulates
autophagy and other responses to cell stress. Recent studies reveal that basal p53 activity
suppresses autophagy, whereas the activation of p53 by certain stimuli induces autophagy
and the activation of p53 by different stimuli results in the PUMA- and NOXA-mediated
apoptosis [40-42]. In addition, low and moderate concentrations of some agents have been
revealed to induce apoptosis, but increasing the concentration of the same agent triggers
necrosis. The challenge is, therefore, not only to understand the mechanisms leading to cell
death but also to categorize the connection at the molecular level between different modes of
the cell death.
In this chapter, we discussed the natural compounds and their mechanisms by which they
induce apoptotic and autophagic cell death in cancer cells and their potential as a novel strategy
for the treatment of cancer. We also presented the results of our previously published natural
compounds screened against gastric cancer [43]. The screen was used to identify new targets
to combat cancer or to identify selective natural compounds those target to apoptosis or
autophagy signaling pathways. In this chapter, we reviewed the main effects of natural
compounds on the different autophagic cell death signaling pathways. In addition, we focused
on highlighting several representative plant-derived natural compounds such as curcumin,
resveratrol, evodiamine, oridonin, and magnolol (structures of these compounds are shown
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in Fig. 1) that may lead to cancer cell death - for regulation of some core autophagic pathways,
involved in Ras-Raf signaling, Beclin-1 interactome, BCR-ABL, PI3KCI/Akt/mTOR, FOXO1
signaling, the NF-κB-mediated pathway, the PI3K/Akt signaling pathway, p53 and other main
pathways. Two of the identified autophagy inducer natural compounds, magnolol and
evodiamine, have been discussed in detail, while the other natural compounds, which had
shown an essential role in autophagic cell signaling pathways, been reviewed recently by
Zhang et al., 2012 [44].
Figure 1. The structure of natural compounds that act on autophagic cell signaling pathways.
2. Methods
The rationale for overall project design was based on assumptions as presented above, which
were motivated by the set of issues. The main goal of the study was to explore naturally
occurring compounds that exhibit cytotoxic activity toward cancer cells. To search for
compounds with significant cytotoxic activity and unprecedented chemical structures from a
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variety of traditional Chinese medicines, the crude ethanolic extracts of 300 species of herbal
plants, traditionally used in China for the treatment of a variety of diseases, and four hundred
TCM compounds were screened. Understanding the interplay of different cancer-related
signaling pathways is important for the development of efficacious multi-targeted anticancer
drugs. Hence, the underlying molecular mechanisms of the above mentioned natural com‐
pounds have been elucidated, which induced cell death.
2.1. Screening strategies
The screening strategy has been shown in schematic form in Fig. 2. Several cancer cells,
including SGC-7901, U87, PANC-1 and A-375 cells were cultured in DMEM supplemented
with 10% fetal bovine serum and were exposed to different Chinese medicinal herbs extracts
and TCM compounds.
Figure 2. Schematic presentation of strategy of identification, isolation, structure elucidation, and screenings of Tradi‐
tional Chinese medicines (TCM) against cancer cells.
2.2. Acridine orange staining
Acridine orange staining assay was performed according to published procedure [45]. In
brief,  cells  were  incubated  without  (control)  and  with  respective  compounds  and  with
rapamycin (positive control group) for indicated time periods and then acridine orange at
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a final concentration of 1 mg ml-1 was added to cells for a period of 20 minutes in the dark
at  37 °C.  Then,  cells  were washed twice with PBS.  Images of  cells  were obtained under
fluorescence microscopy
2.4. Flow cytometric quantification of Acidic Vesicular Organelles (AVOs)
AVOs formation (autophagosomes and autolysosomes) is a characteristic feature of Autoph‐
agy [17]. Furthermore, for quantification of AVOs, we used flow cytometry after the cells were
stained by Acridine Orange (AO) [46]. AO is a weak base that accumulates in acidic spaces
and gives bright red fluorescence (punctate staining (dots) in the cytoplasm which is detected
by fluorescence microscopy and the formation of AVOs can be quantified by flow cytometry.
The intensity of the red fluorescence is proportional to the degree of acidity.
3. Results
The large collections of Traditional Chinese medicinal herbs and natural compounds libraries
have been used to identify anticancer TCM herbs and natural compounds associated with
various cancer specific cellular processes such as apoptosis or autophagy. A list of natural
compounds those expressed cytotoxic activity against gastric cancer cells has been presented
in Table 1 [43]. Using Traditional Chinese medicinal herbs and natural compounds libraries
screen, we discovered several TCM compounds that showed potential anticancer activities
[43]. In a natural compounds screen with glioma brain tumor cells, our results revealed that
alantolactone and Pseudolaric acid B have shown selective anti-glioma activity with lesser
toxic effect over liver and kidney [47,48]. Furthermore, we reported that Dracorhodin per‐
chlorate regulates PI3K/Akt, p53 and NF-κB pathways that are frequently deregulated in
cancer and their simultaneous targeting by Dracorhodin perchlorate could result in efficacious
and selective killing of cancer cells [49]. Through the screen of natural compounds for apoptosis
and autophagic cell signaling pathways, we identified several compounds including costu‐
nolide and xanthoxyletin that induce cell death via apoptotic pathways [50,51]. In addition,
we also found that several compounds such as curcumin, resveratrol, evodiamine, oridonin,
and magnolol induce autophagy and act on autophagic cell signaling pathways (unpublished
data). Furthermore, we examined the role of evodiamine- and magnolol-induced autophagy
in cancer cell death [52,53]. The role of each of the natural compound in autophagic cell
signaling will be discussed later in this chapter.
4. Discussion
4.1. The role of natural compounds in autophagic cell signaling
Plants have a long recorded history to employ in the treatment of cancer [54] and represent
the most important direct antecedent to contemporary anticancer drugs [55]. Recently, some
of the most encouraging clinical evidences and promising anticancer natural herbal com‐
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pounds let us to reconstruct the story of these plants and their ultimate role in chemotherapy
[56]. To provide a paradigm of the most contemporary progress in this field, there were number
of compounds namely artesunate, homoharringtonine, arsenic trioxide and cantharidin
isolated from natural products and have the potential for use in cancer therapy. For many
years, apoptosis has taken a center stage as the most important mechanism of programmed
cell death in mammalian tissues. Apoptosis is a common mode of action for chemotherapeutic
agents including natural product-derived drugs [57,58]. Four categories of dynamic cellular
activities, which lead to cell death, have been described: apoptosis, autophagy, necrosis, and
mitotic catastrophe [59]. With contemporary development in cancer research, it has also been
increasingly noted that conventional chemotherapeutic agents not only elicit apoptosis but
also activate other modes of cell death such as necrosis, mitotic catastrophe, senescence, and
autophagy [60].
Sr. No English Name Chinese Name M.W IC50 ( μM ) 
1 Artesunate 青蒿琥酯 384.43 44.7±5.3 
2 Isoalantolactone 异土木香内酯 232.318 34.9±3.4 
3 Cucurbitacin Ⅱa 雪胆素甲（雪胆甲素） 574.702 17.9±3.4 
4 Tubeimiside-1 土贝母苷甲 1319.43 20.7±1.3 
5 20(S)-Ginsenoside Rh2 20(S)-人参皂苷Rh2 622.6 18.9±1.3 
6 Shikonin 左旋紫草素 288.295 19.7±0.9 
7 Cepharanthin 千金藤素 606.707 20.4±3.6 
8 Evodiamine 吴茱萸碱 303.358 11.7±1.9 
9 Chelerythrine 白屈菜红碱 348.36 18.4±2.6 
10 Patchouli alcohol 百秋李醇 222.366 29.3±3.8 
11 Dracorhodin perchlorate 血竭素高氯酸盐 366.75 54.9±4.3 
12 Resveratrol 白藜芦醇 390 16.4±2.7 
13 Podophyllotoxin 鬼臼毒素 414.405 19.4±2.7 
14 Oridonin 冻凌草甲素 364.43 18.4±0.7 
15 Curcumin 姜黄素 368.38 28.7±2.3 
16 Magnolol 厚朴酚 266.33 64.9±4.3 
17 Costunolide 木香烃内酯 232.32 37.7±3.3 
18 Pseudolaric acid 土荆皮乙酸 430.491 8.7±1.9 
Table 1. MMT assay results of the cytotoxic activities of various compounds against cancer cells with their IC50 values.
Autophagy represents a major route for degradation of aggregated cellular proteins and
dysfunctional  organelles.  Accumulated  lines  of  evidence  have  recently  revealed  that
targeting  autophagic  signaling  pathways  might  be  a  promising  avenue  for  potential
therapeutic purposes. Alterations in autophagy are thought to play an important role in the
pathogenesis of many diseases—for example, Autophagy is closely associated with tumors
and plays  an  important  role  in  human tumor  suppression,  so  inducing  autophagy is  a
potential  therapeutic  strategy  in  adjuvant  chemotherapy  [61,62].  Many  studies  have
demonstrated  that  anticancer  agents  induce  autophagy,  leading  to  the  implications  that
autophagic cell death may be a vital mechanism for tumor cell killing by these agents [63]
and are beneficial in the context of various models of cancer cells. The autophagy machi‐
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nery  interfaces  many  cellular  stress-response  pathways,  and  recent  studies  depict  that
defects in autophagy lead to cancer cell proliferation [64]. The regulation of autophagy in
cancer cells can enhance tumor cell survival, yet can also suppress the initiation of tumor
growth. Understanding the signaling pathways involved in the regulation of autophagy is
crucial to the development of anticancer therapies [21].  In this chapter, we reviewed the
natural  compounds  molecular  mechanisms  of  autophagy  and  examined  ongoing  drug
discovery strategies for modulating autophagy for therapeutic benefits.  The natural anti-
tumor agents have led to enhanced enthusiasm for the development of drugs that target
the  various  aspects  of  the  autophagic  pathways.  Some of  these  autophagic  cellular  ap‐
proaches by representative natural compounds in autophagic induced cell death have been
outlined in Fig. 3. In addition, magnolol and evodiamine have been illustrated in detail.
4.2. Magnolol
In our own studies, performing the screen for natural compounds that induce autophagy, we
identified magnolol [52]. Magnolol, a natural compound, has been reported to inhibit growth
in a variety of tumor cells [65]. Several researchers reported that magnolol-induced cell death
involve apoptosis while Li et al [66] reported that magnolol-induced death occurs via autoph‐
agy but not apoptosis. We observed that there was no significant formation of AVOs at low
concentration while AVOs were formed at a higher concentration of magnolol treated cells.
The formation of acidic vesicular organelles (AVOs) is one of the characteristic features of cells,
which passes through process of autophagy after their exposure to different autophagy
inducer agents [67,68]. Autophagic vacuoles (AV) or autophagosomes are formed as result of
sequestering of parts of the cytoplasm or entire organelles respectively during the process of
autophagy [62]. Currently autophagic cell death has been studied as a potential method for
cancer therapy. To determine the role of magnolol-induced autophagy in killing the SGC-7901
cells, we added the autophagy inhibitor, 3-methyladenine (3-MA), which controlled autoph‐
agy pathway at various points [8]. In contrast to the previous report [69], it was found that
magnolol-induced cell death was not suppressed when treating the cells in combination with
3-MA. These results showed that magnolol-induced autophagy is not involved in the induction
of SGC-7901 cell death. In addition, the findings also demonstrated that magnolol-induced
autophagy may has an effect on ATP level in the SGC-7901 cells and supported those obser‐
vations which showed that autophagy may alter the morphological and cellular events (ATP,
cells blebbing and DNA fragmentation) that take place in apoptotic cell death, without leading
to cell death in itself [8].
4.3. Evodiamine
Evodiamine is a naturally occurring quinolone alkaloid found in the fruit of Evodia rutaecar‐
pa. The data of several studies concerning the cytotoxic activity on cancer cells demonstrated
that evodiamine inhibited the growth of several tumor cells [70]. Results from our screen
indicate that evodiamine induced apoptosis and autophagy simultaneously in human gastric
cancer cells. Evodiamine has been reported as an inducer of autophagy in human cervical
carcinoma HeLa cells [71]. Autophagy is closely associated with tumors and plays an impor‐
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tant role in human tumor suppression, so inducing the autophagy is a potential therapeutic
strategy in adjuvant chemotherapy [61,62]. When the cells are exposed to various autophagy
inducer agents, they form acidic vesicular organelles, which is an important characteristic of
autophagy [67,68]. Thus, we observed the effect of evodiamine treatment on the formations of
AVOs in SGC-7901 cells using fluorescence microscopy after staining with the lysosomotropic
agent, acridine orange (AO). These findings indicate that evodiamine, a natural compound,
has the potential to activate autophagy in gastric cancer cells. This result of evodiamine is also
consistent with the results of the studies reporting that natural compounds can induce
autophagy in various cancer cells. We also demonstrated that evodiamine-induced cell death
was partially suppressed when the cells were treated in combination with specific autophagy
inhibitor, 3-MA. These results showed that evodiamine-induced autophagy was partially
involved in the cell death of cancer cells [52]. While our recent studies demonstrated that
autophagy inhibition enhanced evodiamine-induced apoptosis in prostate cancer cells,
indicating a survival function of autophagy (unpublished data). These results corroborate the
line of evidence demonstrating that evodiamine-induced autophagy, implicated in cell
survival, contributes to the cytoprotective role of autophagy [71,72]. These facts demonstrated
that there is still a great discrepancy between roles of natural compounds-induced autophagy
in cancer cells. The role (or more likely roles because as we discuss, distinct functions for
autophagy occur at different times) of natural compounds-induced autophagy in cancer, is a
topic of intense debate. These responses might vary with cell type and type of stress, and will
undoubtedly reflect the nature of the mutational events occurring in the tumor cells, not only
that of BECN1 and the PI3K pathway as described above, but also p53 status [73,74]. Moreover,
it is believe that in short term assays, the phenomenal protection caused by autophagy
inhibition may be due to delay in cell death instead of true protective effect and this inhibition
causes an increase in tumor cell clonogenic growth after drug treatment. In most of the
examples cited above, this appears as a starking effect, as the whole debate is about the drug
induced autophagy and in response to which the cells die (or cells found dead). This novel
approach emerged as an important point because a recent study also supports this myth that
rapamycin-induced autophagy can protect various tumor cell lines against apoptosis induced
by general apoptotic stimuli [75] and may have a similar effect on the action of anticancer
agents. Moreover, similar to etoposide [74], it has been observed that knockdown of Atg genes
does confer a clonogenic survival advantage to cells after treating with anticancer agents and
the used cells have profound defects in their apoptosis machinery [73,74].
4.4. Role of autophagy in cancer: Science or myth?
It is generally believed that the complex two-faced nature of autophagy in tumor cell survival
versus death may help in determining cancer therapeutic potential. So inhibiting autophagy
may enhance anti-cancer drugs efficacy fairly used in chemo- and radiotherapy-induced
activation of autophagic signaling pathways and which may augment anti-tumor activity, and
thus efficacy of radiation and/or anti-cancer drugs. We are still at the initial stages of under‐
standing the complex interplay of autophagy and cancer, but it is incontrovertible that
autophagy is deeply integrated into metabolism, stress response and cell-death pathways [64].
Preliminary evidences, in addition to some natural compounds that induced autophagic cell
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death, support the idea that natural compounds-induced autophagy enhances tumor cell
survival. Anticancer agents that can be involved in the induction of autophagy include
tamoxifen, arsenic trioxide, rapamycin, histone deacetylase inhibitors, temozolomide, ionizing
radiation [63], vitamin D analogues [76], and etoposide [74]. In addition, several natural
compounds, (curcumin, resveratrol, evodiamine, oridonin, and magnolol) in our natural
compounds libraries screen for autophagy inducer, were found to be involved in autophagy.
However, despite the above examples, is autophagy really an important cell death mechanism?
is highly controversial.
Controversy remains as whether autophagy limits or promotes tumor malignancy, till genetic
inactivation of autophagy, is found to promote tumorigenesis constituting a new category of
tumor suppressors including Beclin 1. Some of the oncogenes including PI3K/AKT/mTOR and
Bcl-2 inhibit autophagy causing tumor cells proliferation, while the other oncogenes including
Ras and myc stimulate autophagy [63]. The significance of autophagy at different stages of
tumor progression can be evaluated considering these kaleidoscopic effects. Further investi‐
gations on natural compounds into the impact of autophagy inactivation are warranted. All
of the above data draw many questions in autophagy mechanistic pool focusing whether
autophagy is really an important mechanism of tumor cell killing by anticancer agents in cells
having ability to undergo apoptosis. Rigorous examination also manifest the speculation
whether bona-fide cancer drugs are actually capable of killing tumor cells via autophagy, is
needed. To answer these questions is the need of the hour, as it may determine the route causes
and may best streamline the contradictory approaches in developing effective combination
therapies by regulating autophagy along with anticancer agents. In conclusion, we now have
sound justifications to visualize that manipulation of autophagy may provide a useful way to
prevent cancer development, limit tumor progression, and increase the efficacy of cancer
treatments. This comprehension seems reasonable due to the fact that drugs induce autophagy,
such as rapamycin (as discussed above), and is rapidly gaining a better understanding of how
Figure 3. Representative natural compounds (Resveratrol, Oridonin, Curcumin, and Evodiamine) targeting autophagic
pathways.
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this process works based on the effects of targeted inactivation of autophagy regulators in
mouse models and human tumor cells. More contradictory messages come when we consider
how autophagy affects the ways by which the tumor cells die when we treat them with
anticancer agents. Over the last several decades the therapeutic use of natural compounds that
induce autophagy has been leading us to the implications that autophagic cell death may be
a vital mechanism of tumor cell killing by these agents.
5. Concluding remarks and future perspectives
Accumulated lines of evidence have recently revealed that targeting autophagic signaling
pathways may be a promising avenue for potential therapeutic purposes. Although this
chapter has focused on natural compounds and their role in autophagic cell signaling path‐
ways, future studies investigating the mechanisms of natural compounds-induced autophagy
and their role in cancer cell death. Progress towards better treatment and understanding by
natural compounds may be made by further examining the role of natural compounds and
crosstalk between the apoptosis and the autophagy. Despite these obstacles, many compounds
bring the hope that with sufficient modification by tools of structural biology and combina‐
torial chemistry, it might be possible to derive sufficiently potent drugs to target core autoph‐
agy pathways, and even autophagic networks in cancer cells, rather than their individual gene
or protein components. Indeed, as discussed above, the generally used cancer therapeutics,
especially natural compounds abolish tumors by inducing apoptosis and autophagy. On the
other hand, a better but growing setting approach is required to make a distinction between
the survival-supporting and death-promoting roles of autophagy. Furthermore, for selectivity
and specificity, role of autophagy, along with the elucidation of the signaling pathways those
confer the autophagic response downstream of different stimuli and activate the specific and
therapeutic response, is desired.. In the end we have coherent arguments in favor of principal
paradigm that disease-associated autophagy could be selectively targeted for therapeutics.
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